Avadel Pharma (AVDL) Misses Q4 EPS by 4c

Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of ($0.32), $0.04 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $19.45 million versus the consensus estimate of $18.21 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Accenture downgraded by TD Cowen on AI concerns